• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

    8.550 +0.080 (+0.94%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Amicus Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics
     
    Via Benzinga
    The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
     
    Via Benzinga
    Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
     
    Via Benzinga
    Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights
     
    Via Benzinga
    Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts
     
    Via Benzinga
    Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
     
    Via Benzinga
    Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
    Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... 
    Via Benzinga
    Topics Intellectual Property Lawsuit
    Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday
     
    Via Benzinga
    Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
    Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
    From Kaskela Law LLC
    Via Business Wire
    UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024
    FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
     
    Via Benzinga
    FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024
    FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Stock Sees RS Rating Improve To 74
    In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.